CoChat

Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

Background The role of incretin-based drugs in the treatment of patients with type 2 diabetes admitted to hospital has not been extensively assessed. In this study, we compared the safety and efficacy of a dipeptidyl peptidase-4 inhibitor (sitagliptin) plus basal insulin with a basal-bolus insulin regimen for the management of patients with type 2 diabetes in general medicine and surgery in hospitals. Methods We did a multicentre, prospective, open-label, non-inferiority randomised clinical trial (Sita-Hospital) in five hospitals in the USA, enrolling patients aged 18-80 years with type 2 diabetes and a random blood glucose concentration of 7·8-22·2 mmol/L who were being treated with diet or oral antidiabetic drugs or had a total daily insulin dose of 0·6 units per kg or less, admitted to general medicine and surgery services. We randomly assigned patients (1:1) to receive either sitagliptin plus basal glargine once daily (the sitagliptin-basal group) or a basal-bolus regimen with glargine once daily and rapid-acting insulin lispro or aspart before meals (the basal-bolus group) during the hospital stay. All other antidiabetic drugs were discontinued on admission. The randomisation was achieved by computer-generated tables with block stratification according to randomisation blood glucose concentrations (ie, higher or lower than 11·1 mmol/L). The primary endpoint of the trial was non-inferiority in mean differences between groups in their daily blood glucose concentrations dur…

Overview

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(16)30402-8

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 30 references

Research works printed but not linked: 1

  1. Seley, 2009, Position statement: inpatient glycemic control, Diabetes Educator, 35, 65

Cited by

See all 171

Metadata

Authors
Pasquel, F. J., Gianchandani, R., Rubin, D. J., Dungan, K. M., Anzola, I., Gomez, P. C., Peng, L., Hodish, I., Bodnar, T., Wesorick, D., Balakrishnan, V., Osei, K., & Umpierrez, G. E.
Affiliations
  • Emory University (US)
  • University of Michigan (US)
  • Temple University (US)
  • The Ohio State University (US)
Corresponding author
Umpierrez, Guillermo E
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2017-02
Volume
5
Issue
2
Pages
125-133
ISSN
2213-8587 (ISSN-L)
OpenAlex
W2560368270
Cited by
168
References
30
Citations by year
2026: 8 · 2025: 10 · 2024: 14 · 2023: 15 · 2022: 18 · 2021: 20 · 2020: 25 · 2019: 22 · 2018: 22 · 2017: 13
FWCI
19.41
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet Diabetes & Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Center for Research Resources
  • Presbyterian Historical Society (1P30DK111024-01, UL1 RR025008)
  • Boehringer Ingelheim
  • Regeneron Pharmaceuticals
  • Eli Lilly and Company
  • Novo Nordisk
  • AstraZeneca
  • American Diabetes Association (1-14-LLY-36)
  • Sanofi
  • National Institutes of Health
  • Merck
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
sitagliptin, type 2 diabetes, hospital management, DPP-4 inhibitors, basal insulin, glargine, multiple daily insulin injections, insulin lispro, insulin aspart, glycemic control, hypoglycemia, hyperglycemia, non-inferiority, length of hospital stay, hospital readmission, cost-effectiveness
MeSH terms
Sitagliptin Phosphate, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Female, Hospitalization, Humans, Hypoglycemic Agents, Male, Middle Aged, Prospective Studies, Treatment Outcome, Disease Management, General Practice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial. https://app.cochat.ai/papers/10.1016/s2213-8587(16)30402-8
The paper
Pasquel, F. J., Gianchandani, R., Rubin, D. J., Dungan, K. M., Anzola, I., Gomez, P. C., Peng, L., Hodish, I., Bodnar, T., Wesorick, D., Balakrishnan, V., Osei, K., & Umpierrez, G. E. (2017). Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(16)30402-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.